Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Employees - 256,
CEO - Dr. Vladimir Coric M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 2.30B
Altman ZScore(max is 10): 0.13, Piotroski Score(max is 10): 1, Working Capital: $384246000, Total Assets: $615107000, Retained Earnings: $-1345714000, EBIT: -884606000, Total Liabilities: $191671000, Revenue: $0
AryaFin Target Price - $0.72 - Current Price $22.56 - Analyst Target Price $60.80
| Ticker | BHVN |
| Index | RUT |
| Curent Price | 22.56 |
| Change | -3.59% |
| Market Cap | 2.30B |
| Average Volume | 1.26M |
| Income | -846.42M |
| Sales | 0.00M |
| Book Value/Share | 4.18 |
| Cash/Share | 4.76 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 256 |
| Moving Avg 20days | 10.00% |
| Moving Avg 50days | -18.98% |
| Moving Avg 200days | -41.73% |
| Shares Outstanding | 101.22M |
| Earnings Date | Mar 03 BMO |
| Inst. Ownership | 90.67% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 5.39 |
| Price/Cash | 4.74 |
| Price/FCF | - |
| Quick Ratio | 3.49 |
| Current Ratio | 3.49 |
| Debt/Equity | 0.09 |
| Return on Assets | -150.03% |
| Return on Equity | -198.83% |
| Return on Investment | -185.53% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 48.44 |
| BETA(β) | 4.12 |
| From 52week Low | 42.87% |
| From 52week High | -59.50% |
| EPS | -9.39 |
| EPS next Year | -5.90 |
| EPS next Qtr | -1.69 |
| EPS this Year | 26.30% |
| EPS next 5 Year | 22.09% |
| EPS past 5 Year | -49.78% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -65.63% |
| Sales Y/Y | - |
| EPS Q/Q | -2.09% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -17.47% |
| ATR(14) | 1.94 |
| Perf Week | 10.75% |
| Perf Month | -21.83% |
| Perf Quarter | -42.64% |
| Perf Year | -43.05% |
| Perf YTD | -39.60% |
| Target Price | 60.80 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer